Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib Plus Doxorubicin vs Sorafenib in Advanced Hepatocellular Carcinoma
NCT01015833Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2010
- Primary completion
- May 2015
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of pegylated liposomal doxorubicin in hepatocellular carcinoma (HCC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Overall Survival up to 3 years. Started Feb 2010; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01015833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01015833.